Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Immune response IL-1 signaling pathway


Log In to Post A Comment

Immune response IL-1 signaling pathway

IL-1 signaling pathway

Interleukin-1 (IL-1) is a proinflammatory cytokine produced by activated macrophages,endothelial cells, B cells and fibroblasts. IL-1 stimulates a broad spectrum of immuneand inflammatory responses [1], [2].

There are two forms of IL-1 encoded by distinct genes, IL-1 alpha and IL-1beta. IL-1 induces cellular response through its receptor composed of two subunits,Interleukin 1 receptor type I ( IL-1RI ) and Interleukin 1 receptor accessoryprotein ( IL1RAP ) [3], [4].

Activated by binding of either of its ligands IL-1 alpha and IL-1 beta,IL-1RI binds to the adaptor protein Myeloid differentiation primary response gene 88( MyD88 ) that activates Interleukin-1 receptor-associated kinase 4 ( IRAK4) and Interleukin-1 receptor-associated kinase 1 ( IRAK1 ). The adaptor proteinToll interacting protein ( TOLLIP ) forms a complex with IRAK1 in restingcells and inhibits IL-1-induced signaling by blocking IRAK1 phosphorylation [5], [6], [7]. IRAK4 phosphorylates and activatesIRAK1. The latter subsequently associates with TNF receptor-associated factor 6 (TRAF6 ) causing oligomerization and activation of TRAF6 that stimulates twodistinct signaling pathways leading to the activation of transcription factors Nuclearfactor kappa-B ( NF-kB p50/p65 ) and Activator protein 1 ( AP-1 ) [7], [1].

TRAF6 is a ubiquitin ligase (E3) that functions with the ubiquitin conjugating(E2) complex consisting of Ubiquitin-conjugating enzyme E2 variant 1 ( UEV1A ) andUbiquitin-conjugating enzyme E2N ( UBC13 ) to catalyze the synthesis ofLys63-linked polyubiquitin chains on target proteins including TRAF6 itself.Ubiquitinated TRAF6 then forms a complex with Mitogen-activated protein kinasekinase kinase 7 interacting proteins 1 and 2 ( TAB1 and TAB2 ) andMitogen-activated protein kinase kinase kinase 7 ( TAK1 ). TAK1phosphorylates the Inhibitor of kappa light polypeptide gene enhancer in B-cells kinasebeta ( IKK-beta ), a subunit of the Inhibitor of kB kinase complex (IKK complex).IKK complex is composed of one regulatory subunit, Inhibitor of kappa light polypeptidegene enhancer in B-cells kinase gamma ( IKK-gamma ), and two catalytic subunits,Conserved helix-loop-helix ubiquitous kinase ( IKK-alpha ) and IKK-beta,forming the IKK complex catalytic core ( IKK (cat) ) [8], [9].

TAK1 also phosphorylates and activates Mitogen-activated protein kinase kinasekinase 14 ( NIK ) that phosphorylates IKK-alpha and stimulates its activity[10].

IKK (cat) then phosphorylates the Inhibitor of NF-kB ( I-kB ), leadingto its ubiquitylation and subsequent degradation. This allows NF-kB p50/p65 totranslocate into the nucleus and induce the expression of Interferon regulatory factor 1( IRF1 ), Heme oxygenase 1, Prostaglandin-endoperoxide synthase 2 (COX-2 ), Nitric oxide synthase 2A ( iNOS ), Coagulation factor III (F3 ) and proinflammatory cytokines, such as Tumor necrosis factor (TNF-alpha ), Interleukin 6 ( IL-6 ) and Interleukin 8 ( IL-8 )[11], [7], [12], [13], [14],[8], [15], [16], [17], [9].

Another signaling pathway, TRAF6/ ECSIT homolog ( SITPEC )/Mitogen-activated protein kinase kinase kinase 1 ( MEKK1 ), activates bothNF-kB p50/p65 and AP-1 [18].

TAK1 and MEKK1 are responsible for the phosphorylation and activation ofmitogen-activated protein kinase kinases 3, 4 and 6 ( MEK3, MEK4 andMEK6 ). The three MEKs phosphorylate and activate Mitogen-activated proteinkinases 8-10 ( JNK(MAPK8-10) ) and Mitogen-activated protein kinase 14 (p38alpha ) leading to phosphorylation of the AP-1 subunit, Jun oncogene (c-Jun ) and activation of AP-1 transcription factors, including c-Junhomodimer ( c-Jun/c-Jun ) [19], [20], [7],[21], [22].

p38alpha also phosphorylates Signal transducer and activator of transcription 1( STAT1 ) which up-regulates IRF1 expression. STAT1 and IRF1are involved in iNOS expression [19], [13].

c-Jun-containing AP-1 complexes induce the expression of Heme oxygenase 1,F3, Endothelin-1, Plasminogen activator inhibitor-1 ( PAI1 ),Ceruloplasmin and multiple cytokines, including TNF-alpha, IL-6 andIL-8. [23], [24], [25], [26], [19], [27], [28], [29], [30], [31], [32], [33], [34], [35], [36].